FRA:BSX • US1011371077
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for BOSTON SCIENTIFIC CORP (BSX.DE).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2021-07-28 | Raymond James | Maintains | Strong Buy |
| 2021-07-28 | Credit Suisse | Maintains | Outperform |
| 2021-07-28 | Morgan Stanley | Maintains | Overweight |
| 2021-05-26 | Needham | Downgrade | Buy -> Hold |
| 2021-05-25 | Barclays | Initiate | Overweight |
| 2021-04-29 | Morgan Stanley | Maintains | Overweight |
| 2021-04-15 | Atlantic Equities | Initiate | Overweight |
| 2021-02-12 | Needham | Maintains | Buy |
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 14.24B 12.29% | 16.747B 17.61% | 20.074B 19.87% | 22.464B 11.91% | 24.769B 10.26% | 27.251B 10.02% | 30.103B 10.47% | 33.342B 10.76% | 37.099B 11.27% | 40.995B 10.50% | |
| EBITDA YoY % growth | 3.624B 13.00% | 4.326B 19.37% | 5.368B 24.09% | 6.981B 30.05% | 7.817B 11.98% | 8.826B 12.91% | 9.876B 11.90% | 11.197B 13.38% | N/A | N/A | |
| EBIT YoY % growth | 2.428B 17.24% | 3.057B 25.91% | 4B 30.85% | 6.283B 57.07% | 6.992B 11.28% | 7.896B 12.93% | 9.048B 14.59% | 10.134B 12.00% | N/A | N/A | |
| Operating Margin | 17.05% | 18.25% | 19.93% | 27.97% | 28.23% | 28.98% | 30.06% | 30.39% | N/A | N/A | |
| EPS YoY % growth | 2.05 17.14% | 2.51 22.44% | 3.05 21.51% | 3.49 14.33% | 3.95 13.20% | 4.44 12.54% | 4.98 12.04% | 5.65 13.53% | 6.38 12.96% | 7.12 11.55% |
All data in USD
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | |
|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | 0.80 6.09% | 0.87 16.50% | 0.88 17.06% | 0.94 17.42% | 0.90 13.42% | 0.99 13.28% | 1.00 13.41% | 1.05 12.21% |
| Revenue Q2Q % growth | 5.224B 12.03% | 5.614B 10.93% | 5.666B 11.87% | 5.931B 12.20% | 5.775B 10.55% | 6.22B 10.79% | 6.292B 11.05% | 6.548B 10.40% |
| EBITDA Q2Q % growth | 1.603B 26.42% | 1.756B 8.46% | 1.75B -14.80% | 1.849B -23.44% | 1.724B 7.55% | 1.876B 6.83% | 1.928B 10.17% | 2.064B 11.63% |
| EBIT Q2Q % growth | 1.445B 53.23% | 1.588B 65.76% | 1.593B 51.57% | 1.694B 61.80% | 1.653B 14.39% | 1.794B 12.97% | 1.833B 15.07% | 1.937B 14.34% |
All data in USD
41 analysts have analysed BSX.DE and the average price target is 89 EUR. This implies a price increase of 63.25% is expected in the next year compared to the current price of 54.52.
BOSTON SCIENTIFIC CORP (BSX.DE) will report earnings on 2026-04-22, before the market open.
The consensus EPS estimate for the next earnings of BOSTON SCIENTIFIC CORP (BSX.DE) is 0.8 EUR and the consensus revenue estimate is 5.22B EUR.
The consensus rating for BOSTON SCIENTIFIC CORP (BSX.DE) is 84.8781 / 100 . This indicates that analysts generally have a positive outlook on the stock.